Robeco Institutional Asset Management B.V. Has $7.54 Million Holdings in Vertex Pharmaceuticals Incorporated (VRTX)

Share on StockTwits

Robeco Institutional Asset Management B.V. boosted its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 62.6% during the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 40,986 shares of the pharmaceutical company’s stock after purchasing an additional 15,783 shares during the period. Robeco Institutional Asset Management B.V.’s holdings in Vertex Pharmaceuticals were worth $7,540,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently modified their holdings of the business. Resources Investment Advisors Inc. acquired a new position in shares of Vertex Pharmaceuticals in the 4th quarter valued at $27,000. Oregon Public Employees Retirement Fund boosted its position in shares of Vertex Pharmaceuticals by 16,530.8% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 4,610,881 shares of the pharmaceutical company’s stock valued at $28,000 after purchasing an additional 4,583,156 shares during the period. We Are One Seven LLC acquired a new position in shares of Vertex Pharmaceuticals in the 4th quarter valued at $32,000. Berman Capital Advisors LLC acquired a new position in shares of Vertex Pharmaceuticals in the 4th quarter valued at $35,000. Finally, FTB Advisors Inc. boosted its position in shares of Vertex Pharmaceuticals by 1,618.2% in the 1st quarter. FTB Advisors Inc. now owns 189 shares of the pharmaceutical company’s stock valued at $35,000 after purchasing an additional 178 shares during the period. 94.92% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Vertex Pharmaceuticals stock opened at $166.72 on Thursday. The stock has a market cap of $42.74 billion, a PE ratio of 58.91, a PEG ratio of 2.39 and a beta of 1.56. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.78 and a quick ratio of 3.66. Vertex Pharmaceuticals Incorporated has a 52-week low of $144.07 and a 52-week high of $195.81.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings results on Tuesday, April 30th. The pharmaceutical company reported $1.14 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.65 by $0.49. The business had revenue of $857.00 million during the quarter, compared to analyst estimates of $853.00 million. Vertex Pharmaceuticals had a return on equity of 22.63% and a net margin of 66.01%. The firm’s revenue was up 34.3% on a year-over-year basis. During the same period in the previous year, the company earned $0.76 EPS. Equities analysts expect that Vertex Pharmaceuticals Incorporated will post 3.06 earnings per share for the current fiscal year.

VRTX has been the subject of a number of recent analyst reports. BidaskClub upgraded Vertex Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, March 16th. Cowen reiterated a “buy” rating and issued a $220.00 price target on shares of Vertex Pharmaceuticals in a research report on Wednesday, March 6th. JPMorgan Chase & Co. reiterated a “buy” rating and issued a $209.00 price target on shares of Vertex Pharmaceuticals in a research report on Wednesday, May 1st. Needham & Company LLC reiterated a “buy” rating and issued a $195.00 price target on shares of Vertex Pharmaceuticals in a research report on Wednesday, May 1st. Finally, ValuEngine upgraded Vertex Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Wednesday, May 1st. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and fifteen have given a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $203.35.

In other news, EVP David Altshuler sold 5,624 shares of Vertex Pharmaceuticals stock in a transaction dated Tuesday, February 19th. The stock was sold at an average price of $187.00, for a total transaction of $1,051,688.00. Following the completion of the sale, the executive vice president now directly owns 32,604 shares in the company, valued at approximately $6,096,948. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Jeffrey M. Leiden sold 20,997 shares of Vertex Pharmaceuticals stock in a transaction dated Tuesday, February 19th. The shares were sold at an average price of $186.98, for a total value of $3,926,019.06. Following the sale, the chief executive officer now owns 110,095 shares of the company’s stock, valued at $20,585,563.10. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 81,705 shares of company stock valued at $14,703,196. 0.70% of the stock is owned by corporate insiders.

TRADEMARK VIOLATION NOTICE: “Robeco Institutional Asset Management B.V. Has $7.54 Million Holdings in Vertex Pharmaceuticals Incorporated (VRTX)” was reported by Zolmax and is the sole property of of Zolmax. If you are reading this article on another site, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this article can be accessed at https://zolmax.com/investing/robeco-institutional-asset-management-b-v-has-7-54-million-holdings-in-vertex-pharmaceuticals-incorporated-vrtx/3085645.html.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene.

See Also: What is the Fibonacci sequence?

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Cimarex Energy  PT Lowered to $57.00 at Morgan Stanley
Cimarex Energy PT Lowered to $57.00 at Morgan Stanley
Pivot Token  Reaches 1-Day Volume of $1.91 Million
Pivot Token Reaches 1-Day Volume of $1.91 Million
Regeneron Pharmaceuticals Inc  Receives Consensus Recommendation of “Hold” from Analysts
Regeneron Pharmaceuticals Inc Receives Consensus Recommendation of “Hold” from Analysts
National Bank of Canada  Receives Average Recommendation of “Hold” from Analysts
National Bank of Canada Receives Average Recommendation of “Hold” from Analysts
Stantec  Downgraded by Zacks Investment Research to Hold
Stantec Downgraded by Zacks Investment Research to Hold
Propy  Price Reaches $0.17 on Exchanges
Propy Price Reaches $0.17 on Exchanges


 
© 2006-2019 Zolmax.